TrialGenes, chromosomes & cancer2025

Influence of Cytogenetics on the Outcome of Patients With High-Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide.

Bengt Rasmussen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.